Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trialEllen M. Apperloo, Hiddo J.L. Heerspink, Gozewijn D. Laverman et al.|Nature Medicine|2024Cited by 95
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical studyAnnemarie B. van der Aart‐van der Beek, Hiddo J.L. Heerspink, Ellen M. Apperloo et al.|Diabetes Obesity and Metabolism|2023Cited by 28
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover TrialEllen M. Apperloo, Marcel H.A. Muskiet, Hiddo J.L. Heerspink et al.|Diabetes Care|2025Cited by 3
Author response for "Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomized cross‐over clinical study"Annemarie B. van der Aart‐van der Beek, Hiddo JL Heerspink, Daniël H. van Raalte et al.|Unknown|2023Cited by 0